ImmunoGen Inc expected to post a loss of 14 cents a share - Earnings Preview

ImmunoGen

28/07/2023 18:50

* ImmunoGen Inc  IMGN.OQ   IMGN.O  is expected to show a
rise in
quarterly revenue when it reports  results on July 31. 
    * The Waltham Massachusetts-based  company is expected to
report 
a 241.4% increase in revenue to $48.349 million from $14.16
million a year ago, according to the mean estimate from 11
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ImmunoGen Inc is
for a
loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ImmunoGen
Inc is
$22​, above​ its last closing price of $18.46. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.25       -0.25      -0.16     Beat    35.8
 Dec. 31 2023  -0.29       -0.30      -0.23     Beat    22.5
 Sep. 30 2022  -0.26       -0.25      -0.31     Missed  -21.8​
 Jun. 30 2022  -0.20       -0.21      -0.24     Missed  -13.2
 ​​Mar.        -0.21       -0.21      -0.10     Beat    52.6
 31 2022                                                
 Dec. 31 2021  -1.63       -1.71      -0.17     Beat    90​
 Sep. 30 2021  -0.18       -0.18      -0.18     Met     2.4
 Jun. 30 2021  -0.18       -0.18      -0.15     Beat    17.7
 This summary was machine generated July 28 at 17:50 GMT.  All
figures in US dollars  unless otherwise stated